Statins for treatment of dyslipidemia in chronic kidney disease

Peritoneal Dialysis International

Volumn 26, Issue 5, 2006, Pages 523-539

  Shurraw, Sabin ^a   Tonelli, Marcello ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

Chronic kidney disease; Hemodialysis; HMG CoA reductase inhibitor; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DEATH; DIALYSATE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; LIPOPROTEIN METABOLISM; LIVER DYSFUNCTION; MALNUTRITION; MORTALITY; MYALGIA; NEPHROLOGIST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; RHABDOMYOLYSIS; STROKE;

EID: 33750561096     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600503     Document Type: Review

References (130)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3):S112-19.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296-305.
3. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278(4):313-21.
4. LaRosa JH. National Cholesterol Education Program: Report of the expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults. J Occup Med 1988; 30(10):826-9.
5. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17(6): 1011-17.
6. Griffin BA, Minihane AM, Furlonger N, Chapman C, Murphy M, Williams D, et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin Sci (Lond) 1999; 97(3):269-76.
7. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276(11):875-81.
8. Iuliano L, Mauriello A, Sbarigia E, Spagnoli LG, Violi F. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: effect of vitamin E supplementation. Circulation 2000; 101(11):1249-54.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320(14):915-24.
10. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102(10):1082-5.
11. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10(2):240-5.
12. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353(1):46-57.
13. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96(8):2514-19.
14. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102(16):1886-92.
15. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161(11):1413-19.
16. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002; 160(1):41-8.
17. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983; 106(5 Pt 2): 1191-200.
18. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, et al. Somatic gene transfer of human ApoA-I-inhibits atherosclerosis progression in mouse models. Circulation 1999; 99(1):105-10.
19. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86(2): 379-84.
20. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104(19):2376-83.
21. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256(20):2823-8.
22. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438):937-52.
23. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3):S142-56.
24. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004;140(1):9-17.
25. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998; 13(11): 2833-41.
26. Nishizawa Y, Shoji T, Kawagishi T, Morii H. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 1997; 62:S90-2.
27. Arnadottir M, Nilsson-Ehle P. Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? Nephrol Dial Transplant 1995; 10(12):2381-2.
28. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49(5):1360-71.
29. Heeringa P, Tervaert JW. Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 2002; 11(3):287-93.
30. Kasahara J, Kobayashi K, Maeshima Y, Yamasaki Y, Yasuda T, Matsuura E, et al. Clinical significance of serum oxidized low-density lipoprotein/ beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 2004; 98(1):c15-24.
31. Kimak E, Solski J. ApoA-and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail 2002; 24(4):485-92.
32. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000; 35(5):852-62.
33. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993; 22(1):135-42.
34. Demant T, Mathes C, Gutlich K, Bedynek A, Steinhauer HB, Bosch T, et al. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 1998; 54(6):2064-80.
35. Staprans I, Felts JM, Couser WG. Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism 1987; 36(5):496-501.
36. Subbaiah PV, Rodby RA. Abnormal acyltransferase activities and accelerated cholesterylester transfer inpatients with nephrotic syndrome. Metabolism 1994; 43(9): 1126-33.
37. Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M, Packard CJ, Shepherd J. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990; 39(2):187-92.
38. Stenvinkel P, Berglund L, Heimburger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993; 44(5):1116-23.
39. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4): 607-17.
40. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994; 23(6):828-35.
41. Coresh J, Longenecker JC, Miller ER, 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9(12 Suppl):S24-30.
42. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55(2): 648-58.
43. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16(2):529-38.
44. Avram MM, Fein PA, Antignani A, Mittman N, Mushnick RA, Lustig AR, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989; 87(5N):55N-60N.
45. Sniderman A, Cianflone K, Kwiterovich PO Jr, Hutchinson T, Barre P, Prichard S. Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 1987; 65(3):257-64.
46. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20(4):324-35.
47. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int Suppl 2003; 84:S110-12.
48. Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55(4):1536-42.
49. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61(1):209-18.
50. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int 2003; 64(5):1829-37.
51. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997; 131(2):229-36.
52. Coresh J, Kwiterovich PO Jr, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993; 34(10):1687-97.
53. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, Konig P, Auinger M, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003; 84:S113-16.
54. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46(3): 869-76.
55. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45(3):876-83.
56. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. Metabolism 1991; 40(10):1002-8.
57. Horkko S, Huttunen K, Laara E, Kervinen K, Kesaniemi YA. Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients. Ann Med 1994; 26(4): 271-82.
58. LLopart R, Donate T, Oliva JA, Roda M, Rousaud F, Gonzalez-Sastre F, et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995; 10(4):537-40.
59. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 1995;15(8):342-7.
60. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002; 22(2):220-8.
61. Tanaka Y, Matsuyama T, Ishikura K, Hataya H, Ikeda M, Honda M. Cholesterol ester transfer protein in children on peritoneal dialysis. Perit Dial Int 2004; 24(3):281-6.
62. Asayama K, Hayashibe H, Mishiku Y, Honda M, Ito H, Nakazawa S. Increased activity of plasma cholesteryl ester transfer protein in children with end-stage renal disease receiving continuous ambulatory peritoneal dialysis. Nephron 1996; 72(2):231-6.
63. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6(1): 110-20.
64. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27(1):84-91.
65. Futatsuyama M, Oiwa T, Komatsu Y. Correlation between oxidized low-density lipoprotein and other factors in patients on peritoneal dialysis. Adv Perit Dial 2002; 18: 192-4.
66. Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C, et al. Dyslipidemia in peritoneal dialysis - relation to dialytic variables. Perit Dial Int 2000; 20(3):306-14.
67. Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220(2):143-51.
68. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21(3):275-81.
69. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD:II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990; 37(3):980-90.
70. Fein PA, Fletcher D, Antignani A, Goldwasser P, Jorden A, Lustig A, et al. Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD. Adv Perit Dial 1989; 5: 185-90.
71. Steele J, Billington T, Janus E, Moran J. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis 1989; 79(1):47-50.
72. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58(1): 353-62.
73. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001; 12(7):1516-23.
74. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86(2):475-82.
75. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999; 10(5):1027-36.
76. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48(3):279-88.
77. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12(12): 2603-11.
78. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2003; 84:S117-20.
79. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61(5): 1887-93.
80. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15(5):458-82.
81. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31(2):103-10.
82. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38(6):1251-63.
83. Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis 1996; 28(6):910-17.
84. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291(4):451-9.
85. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 1999; 71:S251-3.
86. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol 2000;11(10): 1889-95.
87. Piccoli GB, Quarello F, Salomone M, Iadarola GM, Funaro L, Marciello A, et al. Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Transplant 1995;10(Suppl 6):72-7.
88. Sreedhara R, Avram MM, Blanco M, Batish R, Avram MM, Mittman N. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 1996; 28(6):937-42.
89. Webb AT, Brown EA. Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl2):S406-8.
90. Pollock CA, Ibels LS, Caterson RJ, Mahony JF, Waugh DA, Cocksedge B. Continuous ambulatory peritoneal dialysis. Eightyears of experience at a single center. Medicine (Baltimore) 1989; 68(5):293-308.
91. Gault MH, Longerich L, Prabhakaran V, Purchase L. Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD. ASAIO Trans 1991; 37(3):M513-M514.
92. Gamba G, Mejia JL, Saldivar S, Pena JC, Correa-Rotter R. Death risk in CAPD patients. The predictive value of the initial clinical and laboratory variables. Nephron 1993; 65(1):23-7.
93. Iliescu EA, Marcovina SM, Morton AR, Lam M, Koschinsky ML. Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 2002; 22(4):492-9.
94. Ohkuma T, Minagawa T, Takada N, Ohno M, Oda H, Ohashi H. C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis 2003; 42(2): 355-61.
95. Avram MM, Sreedhara R, Patel N, Chattopadhyay J, Thu T, Fein P. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patient? Adv Perit Dial 1996; 12:266-71.
96. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292 (5519):1160-4.
97. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996; 325(2):242-8.
98. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81(5):582-7.
99. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92(2):152-60.
100. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35(1):1-10.
101. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
102. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19):1349-57.
103. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14):1001-9.
104. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive Lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14):1425-35.
105. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20):1301-7.
106. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20):1615-22.
107. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364):1149-58.
108. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326):7-22.
109. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110(12):1557-63.
110. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238-48.
111. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39(6):1213-17.
112. Harris KP, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61(4):1469-74.
113. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39(2):283-90.
114. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45(3): 473-84.
115. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol 1997; 10(1):33-40.
116. Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004; 62(4):287-94.
117. Navaneethan SD, Shrivastava R. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2004; 4:CD004289.
118. Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 1995; 43(4):268-77.
119. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl 1999; 71:S134-6.
120. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1):64-70.
121. Ikejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo T, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004; 53(9):1113-17.
122. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43(3):471-8.
123. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003; 16(2):238-44.
124. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61(1):297-304.
125. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45(1):119-26.
126. Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14(10):2556-72.
127. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001; 60(1):350-7.
128. United States Renal Data System. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2001.
129. London GM, Marchais SJ, Metivier F, Guerin AP. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant 2000; 15(Suppl 5):97-104.
130. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3):I-IV, S1-91.